A core tenet of precision oncology is the rational choice of drugs to interact with patient-specific biological targets of interest, but it is currently difficult for researchers to obtain consistent and well-supported target information for pharmaceutical drugs. We review current drug–target interaction resources and critically assess how supporting evidence is handled. We introduce the concept of a unified Cancer Targetome to aggregate drug–target interactions in an evidence-based framework. We discuss current unmet needs and the implications for evidence-based clinical omics. The focus of this review is precision oncology but the discussion is highly relevant to targeted therapies in any area.

精准肿瘤学的核心原则是合理选择药物与患者特定的感兴趣的生物靶点相互作用，但目前研究人员很难获得一致且有良好支持的药物靶点信息。我们回顾当前的药物-靶点相互作用资源，并严格评估支持证据的处理方式。我们引入了统一癌症靶标组的概念，以在基于证据的框架中聚合药物与靶标的相互作用。我们讨论当前未满足的需求以及对循证临床组学的影响。本次综述的重点是精准肿瘤学，但讨论与任何领域的靶向治疗都高度相关。